Pharmaceutical formulation and its use
Patent 6630162 Issued on October 7, 2003. Estimated Expiration Date: 
November 9, 2020. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
November 9, 2020. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 5382600 3,3-diphenylpropylamines, their use and preparation Patent #: 5559269 Inventors
AssigneeApplicationNo. 09/708428 filed on 11/09/2000US Classes:424/458, Containing discrete coated particles pellets, granules, or beads424/457, Sustained or differential release424/459, Organic coatings424/461, Containing polysaccharide (e.g., cellulose sugars, etc.)424/462, Containing solid synthetic polymers424/468, Sustained or differential release type424/469, Discrete particles in supporting matrix424/490, Coated (e.g., microcapsules)424/493, Containing polysaccharides (e.g., sugars)424/494, Cellulose derivatives424/495Ethyl celluloseExaminersPrimary: Page, Thurman K.Assistant: Ware, Todd D Attorney, Agent or FirmInternational ClassesA61K 31/137 (20060101)A61K 9/50 (20060101) Foreign Application Priority Data2000-03-09 SEAbstractThe invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80% after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.Other References
Field of SearchSustained or differential releaseContaining discrete coated particles pellets, granules, or beads Organic coatings Containing polysaccharide (e.g., cellulose sugars, etc.) Containing solid synthetic polymers Sustained or differential release type Discrete particles in supporting matrix Coated (e.g., microcapsules) Containing polysaccharides (e.g., sugars) Cellulose derivatives Ethyl cellulose | |
